MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Celsion Corp

Închisă

0

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Indicatori cheie

By Trading Economics

Angajați

25

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+1220.75% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.3M

14M

Deschiderea anterioară

0

Închiderea anterioară

0

Celsion Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 apr. 2024, 14:38 UTC

Principalele dinamici ale pieței

Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine

Comparație

Modificare preț

Celsion Corp Așteptări

Obiectiv de preț

By TipRanks

1220.75% sus

Prognoză pe 12 luni

Medie 14 USD  1220.75%

Maxim 14 USD

Minim 14 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCelsion Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

$

Despre Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.